# Welcome to the AI MetabolisMX Lab

We are an emerging research group aimed at developing cutting-edge data-driven research in diabetes and metabolism using statistical modeling, high-dimensional analysis and machine learning. 

### Research
-**Data-driven metabolic subtypes**: We are working on addressing heterogeneity of metabolic diseases using multivariate methods and unsupervised machine learning in order to identify reproducible disease patterns with differential risk and treatment responses. Our current focus is on understanding heterogeneity of type 2 diabetes in Mexico and familial combined hyperlipidemia phenotypes.
<br/>
-**Low-cost metabolic risk prediction**: We have developed metabolic scores aimed at providing metabolic risk prediction with higher accuracy using low-coest approaches that can be readily reproduced in primary-care settings. Our focus in on developing these tools primarily to investigate insulin resistance related phenomena, including type 2 diabetes, visceral obesity and non-alcoholic fatty liver disease.
<br/>
-**Clinical research for pathophysiological mediation**: We aim to study metabolic disease mediators in clinical research to undertand mechanisms of disease and assess potential preventive or therapeutic targets for risk prediction in Mexican population.
<br/>
-**Metabolic ageing**: An emerging field for our research goup is to delve into undertansing the interaction between metabolic diseases, ageing and age-related conditions to address the increasing metabolic burden that faces our ever-aging population
<br/>
<br/>
For more details see [my ResearchGate page](https://www.researchgate.net/profile/Omar_Bello-Chavolla).

### Team Members

<div style="float: left"><img src="images/fotoobc.jpg" width="100", style="display:inline;margin:2px 2px 2px 5px;"/></div>

-**Lab Coordinator**: Dr. Omar Yaxmehen Bello-Chavolla, MD PhD - Physician and researcher specialized in Applied Statistics interested in statistical modeling and machine learning as tools to address heterogeneity of metabolic diseases in admixed populations. Developer of the Metabolic Score for Insulin Resistance, the Metabolic Score for Visceral Fat and the SNNN Clusters tool for diabetes subgroup classification.

### Publications
1.	Bello-Chavolla OY, Aguilar-Salinas CA. Factors influencing achievement of low-density lipoprotein cholesterol goals in Mexico: The International ChoLesterol Management Practice Study. Rev Invest Clin. 2019;71(6):408-416. doi: 10.24875/RIC.19003156.
2.	Bello-Chavolla OY, Antonio-Villa NE, Vargas-Vázquez A, Viveros-Ruiz T, Almeda-Valdes P, Gomez-Velasco D, Mehta R, Elias-López D, Cruz-Bautista I, Roldán-Valadez E, Martagón AJ, Aguilar-Salinas CA. Metabolic Score for Visceral Fat (METS-VF), a novel estimator of intra-abdominal fat content and cardio-metabolic health. Clin Nutrition. 2019. In press.
3.	Bello-Chavolla OY, Antonio-Villa NE, Vargas-Vázquez A, Martagón AJ, Mehta R, Arellano-Campos O, Gómez-Velasco DV, Cruz-Bautista I, Melgarejo-Hernandez MA, Muñoz-Hernandez L, Guillén LE, Garduño-García JJ, Alvirde U, Ono-Yoshikawa Y, Choza-Romero R, Sauque-Reyna L, Garay-Sevilla ME, Malacara-Hernandez JM, Tusié-Luna MT, Gutierrez-Robledo LM, Gómez-Pérez FJ, Rojas R, Aguilar-Salinas, CA. Prediction of incident hypertension and arterial stiffness using the non-insulin based METS-IR index. J Clin Hypert. 2019. In Press.
4.	Hernández-Jiménez S, García-Ulloa AC, Bello-Chavolla OY, Aguilar-Salinas CA, Kershenobich-Stanikowitz D. Long-term effectiveness of a type 2 Diabetes comprehensive care program. The CAIPaDi model. Diabetes Res Clin Pract. 2019 Apr 4;151:128-137.
5.	Arellano-Campos O, Gómez-Velasco DV, Bello-Chavolla OY, Cruz-Bautista I, Melgarejo-Hernandez MA, Muñoz-Hernandez L, Guillén LE, Garduño-García JJ, Alvirde U, Ono-Yoshikawa Y, Choza-Romero R, Sauque-Reyna L, Garay-Sevilla ME, Malacara-Hernandez JM, Tusié-Luna MT, Gutierrez-Robledo LM, Gómez-Pérez FJ, Rojas R, Aguilar-Salinas, CA. Development and validation of a predictive model for incident type 2 diabetes in middle-aged Mexican adults: The Metabolic Syndrome Cohort. BMC Endocrine Disorders 2019 19:37.
6.	Vega-Beyhart A, Enriquez-Estrada VM, Bello-Chavolla OY, Torres-Victoria TR, Martinez-Sanchez FD, Lopez-Navarro JM et al. Quality of life is significantly impaired in both secretory and non-functioning pituitary adenomas. Clin Endocrinol (Oxf). 2019; 1-11.
7.	Almeda-Valdes P, Gomez-Velasco D, Arellano-Campos O, Bello-Chavolla OY, Sevilla-González MDR5, Viveros-Ruiz T et al. The SLC16A11 risk haplotype is associated with decreased insulin action, higher transaminases and large-sized adipocytes. Eur J Endocrinol. 2018 Nov 1. pii: EJE-18-0677.R1.
8.	Almeda-Valdes P, Bello-Chavolla OY, Caballeros Barragán CR, Gomez-Velasco D, Viveros-Ruiz T, Vargas-Vázquez A, Aguilar-Salinas CA. Índices para la evaluación de resistencia a la insulina en individuos Mexicanos sin diabetes. Gac Med Mex. 2018;154(Supp 2):S50-S55.
9.	Bello-Chavolla OY, Cortes-Arroyo JE, Vargas-Vázquez A, Quiroz-Compean F, Leal-Gutiérrez G, Barragan-Dessavre M, Martínez-Samano JE. Meningeal syndrome in a patient treated with a combination of immune checkpoint inhibitors for a metastatic melanoma. Rev Neurol. 2018;67(7):279-280.
10.	Ibarra-González I, Cruz-Bautista I, Bello-Chavolla OY, Vela-Amieva M, Pallares-Méndez R, Santiago Y Nevarez DR, Salas-Tapia MF, Rosas-Flota X, González-Acevedo M, Palacios-Peñaloza A, Morales–Esponda M, Aguilar-Salinas CA, Del Bosque-Plata L. Optimization of kidney disfunction prediction in diabetic kidney disease through the use of targeted metabolomics. Acta Diabetol. 2018;55(11):1151-1161.
11.	Sevilla-González MDR, Aguilar-Salinas CA, Muñoz-Hernández L, Almeda-Valdes P, Mehta R, Zubirán R, Bello-Chavolla OY, Gómez-Velasco D, Vargas-Vázquez A, Viveros-Ruíz T, Martagón-Rosado AJ, Cruz-Bautista I. Identification of a Threshold to Discriminate Fasting Hypertriglyceridemia with Postprandial Values. Lipids Health Dis. 2018 Jul 18;17(1):156.
12.	Mehta R, Reyes-Rodríguez E, Bello-Chavolla OY, Guerrero-Diaz AC, Vargas-Vázquez A, Cruz-Bautista I, Aguilar-Salinas CA. Performance of LDL-C calculated with Martin's formula compared to the Friedewald equation in Familial Combined Hyperlipidemia. Atherosclerosis. 2018;277:204-210.
13.	Bello-Chavolla OY and Bahena-Lopez JP, Garciadiego-Fosass P, Volkow P, Garcia-Horton A, Velazquez-Acosta C, Vilar-Compte D. Bloodstream infection caused by S. aureus in patients with cancer: A 10-year longitudinal single-center study. Support Care Cancer. 2018;26(12):4057-4065.
14.	Martagón AJ, Bello-Chavolla OY,  Arellano-Campos O, Almeda-Valdés P, Walford GA,  Cruz-Bautista I, Gómez-Velasco DV, Mehta R, Muñoz-Hernández L, Sevilla-González MDR, Viveros-Ruiz T, Ordoñez- Sánchez ML, Rodríguez-Guillen R, Florez JC,  Tusié-Luna MT, Aguilar-Salinas CA on behalf of the Slim Initiative in Genomic Medicine for the Americas (SIGMA) Type 2 Diabetes Consortium. Mexican carriers of the HNF1A p.E508K variant do not experience an enhanced response to sulfonylureas. Diabetes Care. 2018;41(8):1726-1731.
15.	Bello-Chavolla OY, Almeda-Valdes P, Gomez-Velasco D, Viveros-Ruiz T, Cruz-Bautista I, Romo-Romo A, Sánchez-Lázaro D, Meza-Oviedo D, Vargas-Vázquez A, Campos OA, Sevilla-González MDR, Martagón AJ, Hernández LM, Mehta R, Caballeros-Barragán CR, Aguilar-Salinas CA. METS-IR, a novel score to evaluate insulin sensitivity, is predictive of visceral adiposity and incident type 2 diabetes. Eur J Endocrinol. 2018;178(5):533-544. 
16.	Bello-Chavolla OY, Aguilar-Salinas CA, Avila-Funes JA. Geriatric Syndromes and Not Cardiovascular Risk Factors are Associated with Cognitive Impairment among Mexican Community-Dwelling Elderly with Type 2 Diabetes. Rev Invest Clin. 2017;69(3):166-172.
17.	Rivera-Buendía F, Bello-Chavolla OY, Zubieta-Zavala A, Hernández-Ramírez L, Zepeda-Tena C, Durán-Arenas L. Evaluation of Mexican 'Sicalidad' health quality program. Salud Publica Mex. 2015 Jul-Aug;57(4):329-34.
18.	Bello-Chavolla OY, Antonio-Villa NE, Vargas-Vázquez A, Ávila-Funes JA, Aguilar-Salinas CA. Pathophysiological mechanisms linking type 2 diabetes and dementia: Review of evidence from clinical, translational and epidemiological research. Curr Diabetes Rev. 2019 doi: 10.2174/1573399815666190115151500
19.	Bello-Chavolla OY, Kuri-Garcia A, Rios-Rios M, Vargas-Vázquez, A, Cortés-Arroyo JE, Tapia-Gonzalez G, Cruz-Bautista I, Aguilar-Salinas CA. Familial Combined Hyperlipidemia: Current knowledge, perspectives and controversies. Rev Invest Clin. 2018;70(5):224-236.
20.	Bello-Chavolla OY, Aguilar-Salinas CA. Management of type 2 diabetes in the elderly patient. J Lat Am Geriat Med. 2017; 3:26-36
21.	Bello-Chavolla OY, Rojas-Martinez R, Aguilar-Salinas CA, Hernández-Avila M. Epidemiology of diabetes mellitus in Mexico. Nutr Rev. 2017 Jan;75(suppl 1):4-12
22.	Bello-Chavolla OY, Aguilar-Salinas CA. Comentarios a artículos de actualidad en diabetes. Rev ALAD. 2016; 6:55-61. 

### Relevant links

1. [**Calculation of the Metabolic Score for Insulin Resistance (METS-IR)**](https://jscalc.io/calc/F54ikuywK6rcqXEy)
2. [**Wikipedia page for METS-IR**](https://en.wikipedia.org/wiki/Metabolic_Score_for_Insulin_Resistance)
2. [**Classification of data-driven diabetes subtypes using neural networks**](https://uiem.shinyapps.io/diabetes_clusters_app/)
3. [**Metabolic Diseases Research Unit main page**](http://www.innsz.mx/opencms/contenido/investigacion/uiem/index.html)


### Support or Contact

Having trouble with Pages? Check out our [documentation](https://help.github.com/categories/github-pages-basics/) or [contact support](https://github.com/contact) and we’ll help you sort it out.
